ReviewJournal of mammary gland biology and neoplasia2004
The genetic epidemiology of breast cancer genes.
Review in Journal of mammary gland biology and neoplasia, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 90 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
90 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- The Association of PTEN Gene Mutations with the Breast Cancer Risk: A Systematic Review and Meta-analysis.Biochemical genetics · 2024Pooled it
- Pooled it
- The LSP1 rs3817198 T > C polymorphism contributes to increased breast cancer risk: a meta-analysis of twelve studies.Oncotarget · 2016Pooled it
- Psychosocial and behavioral impact of breast cancer risk assessed by testing for common risk variants: protocol of a prospective study.BMC cancer · 2017Trial
- Trial
- All the Way: A Decade of SIRT1 in Breast Cancer.Biomedicines · 2026Review
- Genotype-phenotype correlations in breast cancer susceptibility: evaluating MMP-2, TYMS, and eNOS variants in the Jordanian population.Scientific reports · 2026Article
- Cardiovascular disease risk after breast cancer treatment in patients with a BRCA1/2 pathogenic variant.Breast cancer research and treatment · 2025Article
- Blood-Based mRNA Tests as Emerging Diagnostic Tools for Personalised Medicine in Breast Cancer.Cancers · 2023Review
- The Role of Race and Insurance Status in Access to Genetic Counseling and Testing Among High-Risk Breast Cancer Patients.The oncologist · 2022Article
- Profile of Male Breast Cancer in Makkah Region of Saudi Arabia: A 4-Year Retrospective Analysis of Radiology and Histopathology.International journal of breast cancer · 2022Article
- Article
- Polygenic Breast Cancer Risk for Women Veterans in the Million Veteran Program.JCO precision oncology · 2021Article
- Prospective Evaluation of the Addition of Polygenic Risk Scores to Breast Cancer Risk Models.JNCI cancer spectrum · 2021Article
- Breast cancer in sub-Saharan Africa: The current state and uncertain future.Experimental biology and medicine (Maywood, N.J.) · 2021Review
- Personalizing Breast Cancer Screening Based on Polygenic Risk and Family History.Journal of the National Cancer Institute · 2021Article
- Next-generation sequencing of BRCA1 and BRCA2 genes in Moroccan prostate cancer patients with positive family history.PloS one · 2021Article
- Breast Cancer Polygenic Risk Score and Contralateral Breast Cancer Risk.American journal of human genetics · 2020Article
- Contralateral breast cancer risk in patients with ductal carcinoma in situ and invasive breast cancer.NPJ breast cancer · 2020Article
- Robust Estimation of Breast Cancer Incidence Risk in Presence of Incomplete or Inaccurate Information.Asian Pacific journal of cancer prevention : APJCP · 2020Article
30 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Genetic susceptibility to breast cancer in women is conferred by a large number of genes, of which six have so far been identified. In the context of multiple-case families, BRCA1 and BRCA2 are the most important. Mutations in these genes confer high lifetime risks of breast cancer and ovarian cancer, and more moderate risks of prostate cancer and some other cancer types. Mutations in the CHEK2 and ATM genes, by contrast, cause much more modest (2-4 fold) risks of breast cancer. Genes so far identified explain approximately 20% of the familial aggregation of breast cancer. The remaining susceptibility genes have, so far, proved illusive, suggesting that they are numerous and confer moderate risks. A variety of techniques including genome-wide association studies, use of quantitative intermediate endpoints, and resequencing of genes may be required to identify them. The identification of such genes can provide a basis for targeted prevention of breast cancer.
Indexed as
Identifiers
15557796What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.